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The surgical community is plagued with a reputation for both failing to engage and to 
deliver on clinical research. This is in part due to the absence of a strong research culture, 
however it is also due to a multitude of barriers encountered in clinical research; particularly 
those involving surgical interventions. ‘Trauma’ amplifies these barriers, owing to the 
unplanned nature of care, unpredictable work patterns, the emergent nature of treatment 
and complexities in the consent process. This review discusses the barriers to clinical 
research in surgery, with a particular emphasis on trauma. It considers how barriers may be 
overcome, with the aim to facilitate future successful clinical research.
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Introduction 
There is a worldwide epidemic of trauma,
which now accounts for 5.8 million global
deaths each year.1 This is only marginally less
than the 7.6 million deaths attributable to
cancer,2 but there is a large disparity in
research activity. The National Library of
Medicine indexes 2.9 million results for the
search term ‘cancer’, but only 890 000 for
‘trauma’.3 Likewise, the US National Institute
of Health clinical trial registrations reveal
41 000 results for ‘cancer’, but just 7000 for
‘trauma’.4
The surgical community has a poor reputa-
tion for delivering high quality trials, as out-
lined by the editor of The Lancet in a
commentary entitled ‘Surgical research or
comic opera: questions, but few answers’.5
Trials in trauma are particularly challenging,
as its unpredictable nature adds to the
difficulties that prevent the successful deliv-
ery of trials.
Surgical research, particularly in the form of
controlled trials, is essential to advance under-
standing, and particularly to avoid a state of
subconscious maleficence which may occur
when techniques are performed without due
scrutiny. It is uncomfortable to consider that
harm through ignorant practice may exist in
‘modern-day’ surgery. However there is little
doubt that it is widespread. An example where
this practice occurred in elective surgery is the
knee arthroscopy. Throughout the 1990s,
650 000 arthroscopies per year were per-
formed in the United States (USA), mostly for
osteoarthritis. However, in 2002 a trial demon-
strated no difference between sham surgery
and intervention.6 Such studies challenge con-
ventional care by rigorous investigation and
prevent unnecessary surgery, with inherent
morbidity and complications. These studies
also highlight the current dichotomy that exists
between medicine and surgery – with medici-
nal products highly regulated and tested
before widespread use, but surgical products
and techniques often widely introduced with
little prior experimental investigation.
The need for surgical trials in trauma is
undisputed, but in order to deliver them, there
is a need to overcome the barriers that prevent
widespread trial development and patient
recruitment. Large research-orientated organ-
isations, such as the National Institute for
Health Research (NIHR) in the United Kingdom
(UK), provide an extensive infrastructure to
enable high quality research. However, recog-
nition of the practical ‘barriers’ by clinicians
and methodologists, is crucial to increase the
quantity and quality of research outputs.
These barriers may exist in a number of guises
and at various stages throughout the research
process. They may manifest as difficulties in
establishing new research studies, or as diffi-
culties in recruiting to established studies,
therefore potentially reducing both power and
generalisability.
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Search strategy
We searched the Cochrane Library, MEDLINE, and
GoogleScholar (from inception to January 2013). We
used the search terms ‘trial’ or ‘clinical research’, along
with the terms ‘barrier’ or ‘obstacle’. We gave priority to
recent publications, but did not exclude commonly refer-
enced and highly regarded older publications. We also
searched the reference lists of articles identified by this
search strategy, and selected those we judged relevant.
Several review articles were included because they
provide comprehensive overviews that are beyond the
scope of this review. The reference list was subsequently
modified during the peer-review process on the basis of
comments from reviewers
Surgeon barriers
‘Equipoise’ is almost certainly the primary barrier to
surgical trial recruitment. It is used to describe a case of
genuine uncertainty related to a particular clinical prob-
lem, and was first described by Freedman.7 If two treat-
ments are believed to have similar efficacy, then
equipoise is said to exist. Surgeons, perhaps through
nature or nurture (i.e. surgical training), are widely per-
ceived to be a decisive group of individuals, amongst
whom uncertainty may have negative connotations
towards success and performance. When a problem has
two different, yet valid, treatment approaches, individual
surgeons often have a very strong preference for one
approach, even though this may be based only on anec-
dote or ‘gut feeling’ – the surgeon is said to lack personal
equipoise. This situation creates an ethical dilemma for
surgeons considering recruiting patients to clinical trials.
There is a widespread belief that if a surgeon ‘knows’, or
has good reason to believe, that therapy A is better than
therapy B, then they cannot ethically participate in a trial
of the therapies. Historically, this philosophy has been
upheld by trial methodologists, who have suggested that
clinicians who ‘know what is best’ should not partake in a
trial, owing to the absence of personal equipoise.8 
There is now increasing recognition amongst trial
methodologists, ethicists and the medical profession that
equipoise is less concerned with the opinions of an
individual clinician, and more focused on those of the
medical community – termed ‘clinical’ or ‘corporate’
equipoise.7 Enrollment to a clinical trial is therefore con-
sidered ethical, if clinical equipoise exists; i.e. there is
genuine disagreement amongst the expert medical com-
munity about the preferred treatment, not merely the
views of an individual surgeon. Surgeons may therefore
ethically engage in a trial, even if they have a personal
belief that one treatment approach is more successful
than another. The first major step to overcome in the facil-
itation of trials in trauma surgery is to encourage and
enable surgeons to divorce themselves of their personal
beliefs, and instead employ the principle of clinical equi-
poise, and focus on the wider ‘public health’ agenda.
Whilst an acceptance of clinical equipoise may enable
surgeons to engage in clinical trials ethically, other con-
cerns also exist. Randomisation is at the heart of high
quality clinical trials, and is used to balance the distribu-
tion of unknown confounders. Surgeons may fear the
process of randomisation,9 believing that this process
instills doubt and uncertainty in their patient. Some
surgeons may perceive this uncertainty as a challenge to
their competence and undermine their clinical decision-
making ability.9,10 
The challenge faced by clinical trialists is therefore to
encourage surgeons to openly acknowledge the doubt
that exists within the surgical community about any
given surgical approach, and to identify shortfalls in
knowledge. An evidence-based treatment strategy may
then be formulated. In situations whereby no evidence
exists, the most appropriate response is to generate
evidence, thus ensuring a net-gain in wellbeing for
patients, and importantly to ensure non-maleficence.
This ‘thirst’ for evidence would change the ethos of sur-
gery, with clinical trial involvement changing from a rare
occurrence, to normal practice. 
After a surgeon agrees to recruit patients into a trial,
and overcomes the ‘fear’ of randomisation, the trial must
be presented to the patient. This presentation must be
balanced, withholding personal beliefs that may inadver-
tently influence recruitment. This is particularly challeng-
ing, as subconscious preferences may be subtly revealed,
or the inevitable question may arise – what would you do
doctor? – which for some may be difficult to resolve.
These problems may be overcome with use of indepen-
dent research practitioners who are employed specifically
to recruit participants and offer an unbiased, impassion-
ate view of the treatments within trial.11 Commonly, a
nurse or physiotherapist who has been through a training
program related to the trial, adopts this role. The employ-
ment of research practitioners is well established and
appears similarly efficacious in terms of recruitment
uptake, as senior investigators with individual
equipoise.12 Research practitioners also reduce the time-
burden of the trial on the recruiting clinicians, which is an
additional commonly cited barrier to trial involvement.13 
Once a surgeon is engaged with a trial and recruitment
begins, their role is to act as a ‘gatekeeper’14; the gate-
keeper is the individual who highlights potential trial
candidates to the research practitioners, advocates trial
engagement as the optimal treatment strategy to
patients, and facilitates adherence to the trial protocol.
The gatekeeper must have influence over the team of
clinicians with whom they have charge, as erroneous or
misleading information in the form of treatment propos-
als, even by the most inexperienced staff, may have an
influence on patient preferences and trial recruitment. A
strong alliance between research team members, the chief
investigator, surgeon ‘gatekeepers’ and research practitio-
ners, is essential to maximise recruitment.14 The chief
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investigator is key to this alliance, and must have “charm
with brains’’14; the ability to act as the intermediary
between surgeons and methodologists, and to under-
stand the wants and needs of both groups of individuals. 
Surgeon barriers cannot always be overcome, and
outlier surgeons may exist for whom trial engagement is
not possible. The ability for such surgeons to ‘opt out’ is
likely to be the optimal strategy, as they are unlikely to
convey equipoise, are therefore unlikely to successfully
recruit, or may introduce bias. However, ‘opt-out’ should
be reserved as a last resort tactic, as this may introduce
bias, and limit the generalisability of the findings. Provi-
sion should be made for patients to be offered trial
involvement, even if their treating surgeon is an ‘outlier
surgeon’, as this would ensure that an evidence-based
approach is universally offered, and would help to ensure
the generalisability of the results. Such provision may be
made via a local colleague, or through a trial network
established by the chief investigator to spread equipoise.
Patient barriers
Amongst the patient barriers to trial recruitment, treat-
ment preference is arguably the most important. Patients
may have preconceived ideas of the optimal treatment
strategy, which may be based on non-expert experiences
or information from the media, and some may have sought
the particular expertise of a specific surgeon with a desire
to pursue a predetermined treatment. Strong prior patient
preferences limits the generalisability and validity of trials,
owing to a reduction in recruitment and a tendency to
switch intervention groups post-randomisation.15,16
Additionally, patients with a strong preference who are
randomised to receive their desired intervention, have bet-
ter outcomes than those with no preference randomised to
the same intervention.17 Patient preference therefore
should be acknowledged, discussed and documented at
an early stage, in order to adequately address the concerns
of patients, and later to analyse the results of a trial
adequately. Preference is perhaps less of a challenge in
trauma surgery compared with elective surgery, as time
frames to surgery are reduced, and the access by individu-
als to resources are restricted owing to illness, confinement
to hospital and the unplanned nature of care. Neverthe-
less, patients are likely to formulate an early opinion of
what they consider the optimal treatment strategy, which
should be considered when planning trials. 
Researchers must ensure that patients can actively
engage in the research, and plainly see the clinical
problem, with equivalent risks and benefits evident; trial
balance is important whereby the risk-benefit profile of
each intervention seems equivalent to the patient. A
stream of qualitative research during the trial preparation
and development is important to ensure that a trial is
balanced. Qualitative research seeks to explore the under-
standing of patients with regards to the disease, and the
proposed research study. The outcome of the qualitative
work is to determine what more could be done to inform
and engage patients, with the aim to maximise recruit-
ment. 
An example demonstrating successfully the impor-
tance of balance was a urology study of interventions for
prostate cancer (surgery vs radiotherapy vs observa-
tion).18 Patient-centred qualitative research increased
recruitment in this study from 40% to 70% in less than one
year. Key aspects of balance were to ensure that all aspects
of a trial are presented in similar detail, and with similar
enthusiasm. Balance is particularly problematic when a
study involves both a radical (i.e. surgery) and non-radical
(i.e. observation or physiotherapy) treatment option.
Researchers within the prostate cancer study identified
that clinicians tended to present ‘watchful waiting’ to
patients with a palpable reluctance, and as the final treat-
ment regime offered. Patients subsequently interpreted
‘watchful waiting’ as a ‘neglectful’ or a ‘watch them die’
approach, and were subsequently reluctant to engage
with the study. One of the key changes driving increased
recruitment was simply to change the ethos from ‘watch-
ful waiting’, to ‘active monitoring’. Clinicians were encour-
aged to discuss the merits of ‘active monitoring’ with
detailed information of the monitoring process, and to
introduce this as the first treatment option discussed. A
similar approach may be translated into trauma surgery,
with interventions such as surgery versus conservative
treatment, better presented as surgery versus individual-
ised exercise therapy or similar. 
An aversion to randomisation is another barrier among
patients. Researchers within the prostate cancer study
identified that whilst patient aversion to randomisation
was a concern, this was more often a subtle effect of a lack
of clinician equipoise.18 Therefore, if the research team
was not completely committed to the study, even if they
were outwardly in favour of the trial, this would often sub-
consciously be detected by the patients and expressed as
uncertainty in the randomisation process. Whilst there
may be some patients who genuinely have reservations
concerning the process of randomisation, the suggestion
is that this barrier is frequently a symptom of other barriers
(i.e. surgeon equipoise, study balance, patient under-
standing), and not a true aversion to the process.
Intervention concealment, or blinding, and the use of
placebos, or sham surgery, may also pose particular
difficulties and concerns for patients in surgical trials. Sham
procedures are sometimes used, and these may have
elaborate designs, such as in the case of the large 2008
knee arthroscopy trial.6 In this trial, individuals in the non-
intervention group had standard arthroscopy incisions
made, the knee manipulated, and all equipment asked for
by the surgeon as if the procedure were being performed,
no instruments were placed inside the knee. However,
patient concern was reflected in the low recruitment of
only 40% of eligible participants, which may limit the gen-
eralisability. Ethical difficulties and patient concerns,
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remain a key issue for trials using blinding or placebo inter-
ventions in surgery.19,20 These barriers are difficult to over-
come, though sham surgery is the gold-standard means
by which to test surgical procedures, in the form of
randomised double-blind placebo controlled trials.
Some of the barriers experienced by patients may be
overcome by providing adequate materials to enhance
their understanding. These must be used carefully to pro-
vide factual and well-balanced information. The provision
of information is known to be an intervention which may
maximise recruitment, with evidence suggesting that
increasing the awareness of the disease under investiga-
tion (i.e. via an interactive computerised information
sheet, a disease orientated video, or attendance at an edu-
cation session) has a positive effect on recruitment.12
However, increasing the awareness of the research pro-
cess rather than the disease, does not appear to improve
recruitment, and instead provides unnecessary detail.12
Terminology may be a barrier amongst patients. In the
most basic form even the words ‘randomisation’ and
‘trial’ are used in research somewhat out of context to the
usual use in society. ‘Randomisation’ is generally per-
ceived to mean ‘haphazard’ or ‘disordered’, whilst ‘trial’ is
often interpreted by patients as a flippant ‘try and see’
approach, often in the context of a ‘free trial’. This may
therefore not convey the methodological rigour, scientific
support and ethical review that have undoubtedly
occurred in order to enable the trial to proceed. This may
easily confuse patients, but simple substitutes, such as
‘study’, are generally clearer and more acceptable. This
barrier may appear trivial, yet is nevertheless real, and
researchers may be so engrossed within their study that
they miss such subtle barriers. 
Other generic patient barriers must also be considered,
including the time required for participation and the
financial cost to patients, through repeated hospital
attendances. The trial therefore needs to be efficient, such
that the maximum information is extracted during the
minimum number of clinical contacts; ideally part of
‘routine clinical care’. Alternative forms of contact may be
considered, such as mail or electronic communications,
although the effect that these may have on patient follow-
up and retention must be considered.
Disease barriers
Diseases, or specific patterns of trauma, may generate
their own specific barriers. Disease frequency is perhaps
the most obvious barrier, as studies of rare conditions are
undoubtedly more difficult to undertake, yet neverthe-
less the societal burden from such diseases may be great.
Ensuring the optimal number of patients within studies
may require the involvement of multiple centres, or lon-
ger trial recruitment periods, in order to ensure that ade-
quate statistical power is achieved. An alternative is to
accept a reduced statistical power (i.e. the ability to
detect only a very large effect size), yet this approach may
be less acceptable to major funding bodies. Feasibility
studies are therefore an integral part of clinical research,
in order to determine the likely numbers of patients avail-
able for recruitment, and to ensure that recruitment rates
are maximised amongst eligible patients. Feasibility
studies can be completely independent from a full trial, or
in-built with progression to the full trial after a defined
period if specific ‘stop-go’ criteria are met.
The predilection of diseases for certain social groups is
also a barrier to clinical research. Population data sug-
gests that major trauma occurs in men, in socioeconomi-
cally deprived groups, and in minority enthic groups.21
However, trial data suggests that the highest trial attrition
rates occur amongst men, the socioeconomically
deprived, and those from minority ethnic groups.22-24
This discrepancy must therefore be addressed early in the
study design of such disease states. Higher drop-out rates
of participants must be anticipated by accounting for
these in power calculations, and ensuring maximal
recruitment and follow-up in the feasibility stages of trial
design. Specific modalities of follow-up may have differ-
ent successes, amongst individuals with different diseases
- it appears unlikely that those with major trauma would
respond well to web-based follow-up, and similarly,
attempting to measure outcomes at distant time-points
appears unlikely to yield research success.
Process barriers
The culture of research within different medical specialties
is very different, and a strong research culture undoubt-
edly drives research success. The comments by the editor
of The Lancet on poor surgical trial outputs, undoubtedly
reflects the absence of a research culture within surgery.5
Currently, patient recruitment to trials is the exception
rather than the norm. Other specialties, such as paediatric
oncology, have a strong research culture with over 70% of
patients enrolled into trials, and most of the remainder
treated according to protocols established through
trials.25 This ethos has driven collaboration and success
such that rare malignancies, with annual UK case numbers
in single figures, may be recruited into international col-
laborative trials, with survival increasing from 10% to over
80%.25,26 In cancer treatment, both patients and clinicians
consider trial recruitment ‘normal’, and perceive that
research will deliver optimal clinical outcomes. Indeed this
may be true, as there is some suggestion that trial partici-
pation may convey an ‘inclusion benefit’, such that
patients within the trial have improved outcomes com-
pared with those treated outside it. This is thought to be a
consequence of closer monitoring of disease amongst
participants.27,28 The ‘inclusion benefit’ is a compelling
argument against the ‘fear’ of randomisation, further sup-
porting patient involvement in trials. A Cochrane review
was unable to authenticate this ‘inclusion benefit’, how-
ever it did offer reassurance to patients that there is no
additional ‘risk’ through clinical trial involvement,
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compared with standard care 29 The culture in orthopae-
dic surgery may be changing in the UK, with several large
multicentre studies underway,30,31 and organised meth-
ods of data-collection becoming routine at a national
level.32,33 Long-term outcome collection is increasingly
becoming part of this routine data. This provides a new
opportunity to deliver cheap, efficient and large-scale clin-
ical trials by allowing randomisation of interventions
within established national cohorts or audits,32,33 with
follow-up made using routinely collected outcome data. 
Consent is considered by many as a barrier to clinical
research, especially for prospective studies of trauma care.
However, consent in research is considered essential, and
has been since outrage erupted after a long-term study of
the natural history of syphilis failed to treat participants
after the discovery of antibiotics; the aim was to under-
stand the natural history of untreated disease.34 This out-
rage was formalised through the Helsinki Declaration
following the Nuremberg trials, which has been continu-
ally updated ever since.35 However, the now-established
process of ‘opt-in consent’ creates challenges. Ran-
domised trials of ‘opt-in’ versus ‘opt-out’ consent strategies
have demonstrated higher rates of recruitment and similar
rates of retention, with an overall gain in participants for
opt-out consent strategies.36 Likewise, an opt-in approach
limits the ‘generalisability’ of the research, with opt-in less
likely amongst those groups with higher rates of study
attrition (i.e. males, socioeconomically deprived and eth-
nic groups). There is a strong argument to suggest that
low-risk studies, particularly those comparing interven-
tions already in common use, should adopt an opt-out
approach,36 though debate continues.
The opt-in consent process may pose a particular prob-
lem for trauma patients, as the ability of an individual to
understand and consider the interventions posed may be
impaired through head injury, pain, shock, medication or
numerous another causes. Similarly, the timescale
between presentation and intervention may be short,
such that an individual is unable to consider the interven-
tions proposed reasonably. The World Medical Associa-
tion Declaration of Helsinki offered pragmatic guidelines
for this purpose.37 The declaration outlines that research
may be carried out on such individuals, whereby the
physical/mental barrier to consent is an integral compo-
nent of the research population. The research protocol
must state that consent to remain in the research should
be obtained from the individual, or a legally authorised
surrogate, as soon as possible. However, a subsequent
European Union (EU) directive (Clinical Trials Directive
2001/20/EC), requires prior discussion with the individ-
ual, or a legal representative, before involvement in a
trial. This directive is widely seen as a barrier to emer-
gency care research within Europe,38 and led to a group
of interested parties (clinicians, lawyers and ethicists)
forming the ‘Vienna Initiative to Save European Research’
(VISEAR).39 This group sought to determine how the
European directive had been implemented throughout
Europe, therefore exposing the interpretive variation of
this directive. Germany has acted upon this directive most
vehemently, requiring a judge to act as the legal repre-
sentative authorising research.39 Other countries, such as
the United Kingdom, have allowed the clinician responsi-
ble for the care of the patient to act as their legal represen-
tative, as long as they are not connected to the conduct of
the trial and that there is no person with a closer relation-
ship to the individual willing or available to act. The EU
has recognised the shortcomings of their directive,
recently announcing plans to revise it in order to better
accommodate emergency situations,40 though some
concern remains about whether the changes will be far-
reaching enough.41 The legislation remains in the consul-
tation phase at present (January 2014).
There are a number of trauma studies, including those
in orthopaedics, that have successfully used the
emergency trauma consent guidelines to good effect.
The clinical randomisation of an antifibrinolytic in signifi-
cant haemorrhage (CRASH-II) trial was the largest trauma
trial to date, with over 20 000 participants enrolled inter-
nationally, investigating the emergency use of tran-
sexamic acid in major trauma.42 Consent was initially
sought from an individual close to the patient (the per-
sonal legal representative), or if immediately unavailable,
a nominated professional legal representative within each
hospital; if both were immediately unavailable, the indi-
vidual was randomised, with later consent from a repre-
sentative as soon as possible. When an individual
regained competence, formal informed consent was
sought for study participation. An example of this model
of consent in orthopaedic trauma is in the Warwick Hip
Trauma Evaluation (WHiTE) Study, which investigates dif-
ferent interventions in fragility hip fractures.43,44 
Delivering changes in clinical practice
Even if research barriers are overcome and the highest
quality research is performed, results do not necessarily
translate into clinical practice. An ethnography by Katz45
identified that “surgeons have been resistant to accept-
ing new scientific findings and applying them to their
practice”. Surgeons frequently suggest that randomised
controlled trials (RCTs) lack generalisability to individual
patients, with this cited as a common reason for the
reluctance to accept RCT evidence.46 Surgeons may inti-
mate that irrespective of how well the RCT is conducted,
outcomes of a study are only useful at group-level, and
may not necessarily apply to the individual. Many
expand this argument by suggesting that RCTs are too
simple to adequately assess the complex nature of sur-
gical interventions, and that there may be many factors
or complexities about the intervention as a whole that
influence outcomes.47 These include individual surgeon
nuances, or peri-operative care regimes, i.e. the care
that occurs outside the environment of the specific
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operative intervention.47 Overcoming these attitudes
involves a culture change, which may be possible by
educating and inspiring the surgical community that
research can successfully improve outcomes, and
empower them to challenge their pre-conceived ideas
through high-quality research. 
Conclusion
Despite the obvious need for trials in trauma surgery,
there is a clear paucity of well-conducted research that
has been undertaken. There are many factors that may act
to prohibit high quality trials, which may relate to the
surgeon, the patient, or the disease under investigation.
Equipoise is the key concern amongst treating surgeons,
and appears to be the most substantial barrier to
research. A united surgical community, who openly
acknowledge uncertainty, would be a powerful force to
drive research. It is likely that such a group could erode
many of the barriers that currently exist, which may lead
to the development of robust programs of clinical
research. However, while RCT evidence in trauma is either
scarce or of poor quality, the impact of evidence from
clinical trials is likely to be limited.
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